A First-in-human Trial of BGB-53038
Phase 1
514
about 2.1 years
18+
4 sites in CA, KS, MD +1
About this study
Researchers are testing a new drug called BGB-53038 to see if it's safe and effective in people with advanced cancers that have KRAS mutations or amplifications. The trial will also explore whether BGB-53038 works better when combined with other medications like tislelizumab or cetuximab.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BGB-53038
- 2.Take Cetuximab
- 3.Take Tislelizumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cetuximab, tislelizumab
injection (Injection)
Primary: Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-53038, Phase 1a: Number of Participants Experiencing Adverse Events (AEs), Phase 1b: Overall Response Rate (ORR)
Secondary: Disease Control Rate (DCR), Duration of Response (DOR), Phase 1a: Single-dose and steady-state Half-life (t1/2) of BGB-53038, Phase 1a: Single-dose and steady-state area under the concentration-time curve (AUC) of BGB-53038, Phase 1a: Single-dose and steady-state maximum observed plasma concentration (Cmax) of BGB-53038, Phase 1b: Number of Participants Experiencing Adverse Events (AEs), Phase 1b: ORR, Phase 1b: Overall Survival (OS)
Oncology